-4.05% for Tilray stock as sellers push below key averages

Traders Union
All News
Financial News
Tilray drops 4.05% today to $6.39

Highlights

Tilray executed its largest Australian expansion to date, introducing new medical cannabis products under Redecan and Good Supply brands.
The company broadened UK beverage operations by acquiring five former BrewDog bar locations, supporting strategic diversification amid continued sector challenges.
Shares trade under persistent downward pressure, with oversold technical indicators and a high probability of drifting within a $6.15–$6.65 range over the next week.

Australian expansion and UK diversification amid sustained selling pressure

On March 19, 2026, Tilray announced its largest expansion to date of its medical cannabis portfolio in Australia, launching new products under the Redecan and Good Supply brands. The company emphasized its ongoing commitment to the regulated Australian market, noting improved patient access to EU-GMP certified medical cannabis through established distribution channels. Tilray also expanded its beverage diversification by adding five former BrewDog bar sites in the UK, as part of efforts to stabilize and grow this segment, though price action has remained under broader selling pressure.

Persistent bearish momentum with oversold signals near key resistance

The current price of $6.39 sits well below the SMA-20 ($7.31), SMA-50 ($7.91), and SMA-200 ($9.46), indicating persistent downward pressure across short-, medium-, and long-term trends. The Ichimoku Kijun level at $7.28 is above the current price, confirming this area as immediate resistance. Momentum signals show strong bearishness, with the daily MACD at -0.41 (Sell) and ADX at 9.65 (Neutral), suggesting a weak but persistent downtrend. Oscillators indicate clear oversold conditions on RSI (32.90), Stoch RSI (0.00), and CCI (-146.11), while sellers decisively dominate intraday momentum per BBP (-0.36, Oversold). AO also aligns with the bearish trend. The daily price is down 4.05% ($0.27 lower), opening just below the previous close (no meaningful gap), and is currently trading near the intraday low of the $6.37 – $6.61 range. Intraday volatility is moderate, and the tone shows continued selling pressure after the open. While momentum is weak, the prevalence of oversold signals suggests potential for a technical bounce, but there is no clear confirmation.

High downside risk as sideways range limits rebound odds

For the next week, a typical volatility band is expected between $6.15 and $6.65. The probability of further price decrease is very high (more than 80%), with a price rebound less likely. The baseline scenario forecasts continuation within a sideways corridor from support at $6.15 to resistance near $6.65. A bullish setup would require a break above immediate resistance at $7.28, while a bearish outcome could see price slipping below $6.15 and accelerating downward.

Anton Kharitonov, expert at Traders Union, notes that Tilray shows persistent technical weakness across all major timeframes. Despite recent efforts to expand in Australia and diversify its beverage business, the stock remains under sustained selling pressure with oversold signals dominating. He sees little indication of a reversal while $6.65 resistance holds, and considers the probability of further decline over 80%. "Until price reclaims $7.28, I remain defensive and do not trust any short-term bounce," Kharitonov says.

Earlier, analysts noted that Tilray faced persistent bearish momentum and ongoing seller pressure despite its expansion and diversification efforts. The current analysis strengthens this view, highlighting continued downside risk with volatility expected to remain elevated, and traders should closely monitor the $6.15 support as a decisive threshold in the coming sessions.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.